Diskussionsleiter: R. Wachter (Göttingen)
(P1408) | Beta blockers and chronic heart failure patients – prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. | |
A. Corletto, H. Fröhlich, T. Täger, M. Hochadel, H. A. Katus, L. Frankenstein, J. Senges (Heidelberg, Ludwigshafen) | ||
(P1409) | The true rate of drug-related cough of the angiotensin converting enzyme inhibitors in placebo controlled trials in cardiovascular medicine: a meta-analysis | |
D. Vukadinovic, D. Lavall, A. Nikolovska Vukadinovic, S. Wagenpfeil, M. Böhm (Homburg/Saar, Homburg) | ||
(P1410) | Treatment with sacubitril/valsartan regarding evaluation for heart transplantation | |
F. Strangl, M. Rybczynski (Hamburg) | ||
(P1411) | Evaluating Internal Medicine Patients’ Comprehensibility of a Standardized Medication Plan (§ 31a SGB V) | |
L. Botermann, K. Monzel, K. Krueger, C. Eickhoff, A. Wachter, C. Kloft, U. Laufs, M. Schulz (Berlin, Homburg/Saar) | ||
(P1412) | Adverse effects of escitalopram on cardiac status and health-related quality of life in the MOOD-HF study depend on heart failure severity at baseline – results of a secondary subgroup analysis | |
D. Knappe, S. Sehner, S. Störk, H. Gunold, F. Edelmann, R. Wachter, H. Schunkert, T. Graf, I. Kindermann, M. Haass, S. Blankenberg, S. Pankuweit, C. Prettin, M. Böhm, H. Faller, J. Deckert, K. Wegscheider, G. Ertl, C. E. Angermann, MOOD-HF (Hamburg, Würzburg, Leipzig, Berlin, Göttingen, München, Lübeck, Homburg/Saar, Mannheim, Marburg) | ||
(P1413) | Impact of Pulmonary Function on Patient-Reported State of Health in Patients with Heart Failure | |
K. Rothmund, N. Nagysomkuti-Merste, M. Breunig, C. Morbach, G. Ertl, C. E. Angermann, S. Störk, F. H. Rutten, G. Güder, S. Brenner, INH (Würzburg; Utrecht, NL) |